As people live longer, age-related disorders, including many neurodegenerative diseases, are becoming increasingly common.

Lipid nanoparticles address key drug delivery challenges, including immune evasion, toxicity, and regulatory approval.

For decades, we've been told “Lower LDL is Better.” But what if, in our myopic obsession with LDL and ApoB, we’ve missed a ...